AbbVie NYSE:ABBV fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share topped the $3.60 consensus, up 22.9%. The quarter carried an unfavorable $0.17 from acquired IPR&D and milestones expense.
Immunology grew 15.1% to $8.79 billion, with Skyrizi up 24.4% to $5.51 billion and Rinvoq up 24.5% to $2.53 billion. Humira fell 35.9% to $756 million. Neuroscience rose 20.3% to $3.23 billion. Oncology declined 1.5% to $1.65 billion as Imbruvica dropped 29.4%, and aesthetics was flat at $1.28 billion, down 0.9% on an operational basis. Adjusted operating margin was 48.3%.
AbbVie cut its 2026 adjusted diluted EPS range to $13.87 to $14.07 from $13.91 to $14.11, a $0.04 reduction at the midpoint. The company attributed the change to $0.14 a share of dilution from the proposed acquisition of Apogee Therapeutics, valued at about $10.9 billion and expected to close in the third quarter, partly offset by $0.10 of operating overperformance.